RxDoctor Payments Data

Eduardo Morfa Romero, MD

Infectious Disease · Bayamon, PRNPI 1518322163

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Viiv Healthcare Company at 29.9% of the total.

$2,462in general payments, 2019–2025

Across 75 payments — averaging $32.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$736
  • AstraZeneca$292
  • Gilead$225
  • AbbVie$210
  • Johnson & Johnson$198
  • Merck$153
  • plus $648 from 15 others

What the payments were for

  • Food & beverage$2,462100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,462 in reported general payments places this provider in the 75th percentile of 127 infectious disease providers in Puerto Rico.

See all infectious disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$29,175
Medicare patients
132
Services billed
277

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Daptomycin18$12,124
Cefepime Hcl18$2,145
Fluconazole13$379
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$198
Doxycycline Hyclate11$125

Paid to pharmacies, not to this prescriber.

Other infectious disease in Bayamon

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →